Mirum and Incyte’s Atebrioz approved for FOP in US
RegulatoryapprovedAtebriozPositive
AI Analysis
Summary
The FDA approved Atebrioz (zilurgisertib), developed by Mirum Pharmaceuticals and Incyte, for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. This represents a regulatory milestone for a therapy targeting a rare genetic disorder.
Outcome Details
FDA approval for treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and above
Importance:9/10
Sentiment:
0.95
FDA approvalAtebriozFOPrare diseaseMirumIncyte
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 28, 2026 6:39 AM